# US 2009/0022806 A1 · Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0022806 A1
- Document ID: US20090022806A1
- Status: Published application
- Kind: A1
- Application number: 12/004,979
- Filed: 2007-12-21
- Published: 2009-01-22
- Earliest claimed: 2006-12-22
- Inventors: Shaker A. Mousa; Paul J. Davis; Aleck Hercbergs
- Web page: https://patentgrep.com/patent/US20090022806A1

## CPC

- A61K 9/5153: {Polyesters, e.g. poly(lactide-co-glycolide)}
- A61B 6/037: {Emission tomography}
- A61K 31/282: Platinum compounds
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 31/4353: ortho- or peri-condensed with heterocyclic ring systems
- A61K 31/505: Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K 31/66: Phosphorus compounds
- A61K 31/69: Boron compounds
- A61K 31/704: attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin {(digitoxin A61K31/7048)}
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 35/00: Antineoplastic agents
- A61B 5/4082: {Diagnosing or monitoring movement diseases, e.g. Parkinson, Huntington or Tourette}
- A61B 5/4088: {Diagnosing of monitoring cognitive diseases, e.g. Alzheimer, prion diseases or dementia}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 9/1075: {Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence)}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61B: DIAGNOSIS; SURGERY; IDENTIFICATION (usefulness limited to only animals A61D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.

## Claims

### Claim 1

A method of suppressing growth of cancer cells which are resistant to drug therapy, comprising administering to a subject in need thereof an amount of tetrac, triac, tetrac and triac nanoparticles or analogs thereof, effective for effective for suppressing the growth.

### Claim 2 (depends on 1)

The method of claim 1, wherein said therapy-resistant cancer cells are selected from the group consisting of a primary or metastatic tumor, breast cancer, thyroid cancer, neuroblastoma, glioma and glioblastoma multiforme and other brain cancers, colon cancer, head-and-neck cancers, melanoma and basal cell and squamous cell carcinomas of the skin, sarcoma, ovarian cancer, prostate cancer, kidney cancer, hepatoma, lung cancer and stomach cancer.

### Claim 3 (depends on 1)

The method of claim 1, wherein said drug therapy comprises administration of conventional or novel chemotherapeutic drugs.

### Claim 4 (depends on 3)

The method of claim 3, wherein the chemotherapeutic drugs are selected from the group consisting of doxorubicin, etoposide, cyclophosphamide, 5-fluorouracil, cisplatin, trichostatin A, paclitaxel, gemcitabine, taxotere, cisplatinum, carboplatinum, irinotecan, topotecan, adriamycin, bortezomib and atoposide or novel derivatives of the foregoing agents.

### Claim 5 (depends on 1)

The method of claim 1, further comprising administering a chemotherapeutic drug.

### Claim 6 (depends on 3)

The method of claim 3, wherein the chemotherapeutic drugs are selected from the group consisting of doxorubicin, etoposide, cisplatin, and trichostatin A.

### Claim 7 (depends on 1)

The method of claim 1, wherein the tetrac or tetrac analog is a nanoparticle conjugate comprising a nanoparticle conjugated to a plurality of tetrac particles with a particle size between 10 and 1000 nm, wherein the tetrac particles are bound to the nanoparticle by an ether (—O—) or sulfur (—S—) linkage bridging the alcohol moiety of the tetrac particles and the nanoparticle conjugation.

### Claim 8 (depends on 1)

The method of claim 1, wherein the tetrac, tetrac nanoparticle or analog thereof is conjugated to a member selected from the group consisting of: polyvinyl alcohol, acrylic acid ethylene co-polymer, polyethyleneglycol (PEG), polylactic acid, polyglycolide, polylactide, agarose, PEO, m-PEG, PVA, PLLA, PGA, Poly L-Lysine, Human Serum Albumin, Cellulose Derivative, Carbomethoxy/ethyl/hydroxypropyl, Hyaluronic Acid, Folate Linked Cyclodextrin/Dextran, Sarcosine/Amino Acid spaced Polymer, Alginate/Carrageenan, Pectin/Chitosan, Dextran, Collagen, Poly amine, Poly aniline, Poly alanine, Polytryptophan, Poly(lactic-co-glycolic acid) (PLGA) and Polytyrosine.

### Claim 9 (depends on 7)

The method of claim 7, wherein the tetrac or tetrac analog is a nanoparticle with a protecting group at the NH2 moiety.

### Claim 10 (depends on 9)

The method of claim 9, wherein the protecting group is selected from the group consisting of N-Methyl, N-Ethyl, N-Triphenyl, N-Propyl, N-Isopropyl, N-tertiary butyl, and other functional groups.

### Claim 11 (depends on 7)

The method of claim 7, wherein the nanoparticle contains between 1 and 100 tetrac or tetrac analog molecules per nanoparticle.

### Claim 12 (depends on 11)

The method of claim 11, wherein the nanoparticle contains between 15 and 30 tetrac or tetrac analog molecules per nanoparticle.

### Claim 13 (depends on 12)

The method of claim 12, wherein the nanoparticle contains between 20 and 25 tetrac or tetrac analog molecules per nanoparticle.

### Claim 14 (depends on 1)

The method of claim 1, wherein the tetrac, tetrac analog or nanoparticle thereof is in a pharmaceutical formulation comprising a pharmaceutically acceptable carrier.

### Claim 15 (depends on 14)

The method of claim 14, wherein the pharmaceutical formulation further comprises one or more pharmaceutically acceptable excipients.

### Claim 16 (depends on 15)

The method of claim 15, wherein the formulation has a parenteral, oral, rectal, or topical mode of administration, or combinations thereof.

### Claim 17

A method of increasing the chemosensitivity of cancer cells by administering to the cells tetrac, tetrac analogs, or nanoparticles thereof in an amount sufficient to enhance the chemosensitivity.

### Claim 18

A method of treating a patient suffering from the presence of a tumor, comprising administering to said patient tetrac, tetrac analogs, or nanoparticles thereof in an amount effective for enhancing the chemosensitivity of cancer cells.
